• Users Online: 319
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ARTICLE
Year : 2011  |  Volume : 2  |  Issue : 4  |  Page : 273-279

Thromboprophylaxis in Cancer Patients Receiving Bevacizumab


1 The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, One Discovery Drive, Rensselaer, NY 12144 USA;
2 The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, One Discovery Drive, Rensselaer, NY 12144 USA; College of Medicine, King Saud University, Riyadh, Saudi Arabia

Correspondence Address:
Shaker A Mousa
Professor of Pharmacology, Vice Provost, Executive Vice President and Chairman, Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer, New York 12144, USA

Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Background: Thrombosis is one of the leading causes of death in cancer patients. Anti-angiogenic inhibitors like bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor, increase the risk of thrombosis. Thromboprophylaxis must be provided to patients receiving bevacizumab. Methods: An up-to-date, comprehensive literature search using PubMed for studies performed on bevacizumab from January 2003 to the present was performed. Key words searched included bevacizumab, avastin, thromboprophylaxis, and anticoagulation in cancer patients. Results: Thrombosis risk is increased with bevacizumab therapy. Anticoagulation therapy with bevacizumab may increase bleeding risks; however, these risks are generally low and for minor bleeding. Current guidelines approve thromboprophylaxis in a subset of cancer patients; however, they are not specific for patients receiving anti-angiogenesis therapy. Conclusion: Thromboprophylaxis should be considered for patients receiving bevacizumab, as the benefits outweigh the small risk of adverse effects such as bleeding.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1388    
    Printed87    
    Emailed0    
    PDF Downloaded3195    
    Comments [Add]    

Recommend this journal